Leora Horn: An update on our recent review published in Trends in Cancer

Leora Horn, Head of Clinical Development, Late Oncology at AstraZeneca, shared a post on LinkedIn:

“Together with co-authors including Charles Swanton and Chris Abbosh as well as AstraZeneca colleagues Jorge Reis-Filho, Darren Hodgson, Davina Gale and Gary Doherty as well as fellow co-authors, I’m pleased to share an update on our recent review summarizing translational implications of data supporting ctDNA-based risk determination in NSCLC.

Published in Trends in Cancer, our review titled ‘Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer’ discusses emerging ctDNA capabilities, to refine tumor-node-metastasis staging; as an early endpoint or to detect treatment resistance up-front in the neoadjuvant setting; and for guiding adjuvant treatment decisions.

We also explore the clinical validity and utility of leveraging ctDNA as a prognostic biomarker and discuss the need to demonstrate improved patient management through interventional clinical trials.

All in all, a fascinating paper to be involved in. Thank you to my co-authors for the great teamwork! ”

Source: Leora Horn/LinkedIn